Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo

TBI-166, derived from riminophenazine analogues, is under development in a phase I clinical trial in China. TBI-166 showed more potent anti-tuberculosis (anti-TB) activity than did clofazimine in in vitro and animal experiments. To identify potent regimens containing TBI-166 in TB chemotherapy, TBI-...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Antimicrob Agents Chemother
Hoofdauteurs: Zhang, Ye, Zhu, Hui, Fu, Lei, Wang, Bin, Guo, Shaochen, Chen, Xi, Liu, Zhongquan, Huang, Haihong, Yang, Tianjian, Lu, Yu
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Microbiology 2019
Onderwerpen:
Experimental Therapeutics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591646/
https://ncbi.nlm.nih.gov/pubmed/31061157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02496-18
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items